Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free IART Stock Alerts

Integra LifeSciences (IART) Financials

Integra LifeSciences logo
$13.43 +2.78 (+26.08%)
As of 03:08 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Integra LifeSciences

Annual Income Statements for Integra LifeSciences

This table shows Integra LifeSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -3.52 75 65 61 50 134 169 181 68 -6.94 -516
Consolidated Net Income / (Loss)		 -3.52 75 65 61 50 134 169 181 68 -6.94 -516
Net Income / (Loss) Continuing Operations		 6.85 75 65 61 50 134 169 181 68 -6.94 -516
Total Pre-Tax Income 		61 90 11 57 60 94 215 214 81 -18 -564
Total Operating Income		 80 115 45 111 94 151 197 239 112 28 -493
Total Gross Profit		 556 643 753 901 953 851 945 970 885 882 832
Total Revenue		 883 992 1,188 1,472 1,518 1,372 1,542 1,558 1,542 1,611 1,635
Operating Revenue		 883 992 1,188 1,472 1,518 1,372 1,542 1,558 1,542 1,611 1,635
Total Cost of Revenue		 327 349 436 571 565 521 598 587 657 728 804
Operating Cost of Revenue		 327 349 436 571 565 521 598 587 657 728 804
Total Operating Expenses		 477 528 708 790 859 700 747 731 773 854 1,325
Selling, General & Admin Expense		 416 456 624 691 688 595 637 616 657 717 700
Research & Development Expense		 51 58 63 78 144 77 93 101 104 115 99
Amortization Expense		 9.95 14 20 21 27 28 17 14 12 21 15
Impairment Charge		 - - - - - - - - 0.00 0.00 511
Total Other Income / (Expense), net		 -19 -25 -33 -54 -34 -58 17 -25 -30 -47 -70
Interest Expense		 24 26 35 65 54 72 50 50 51 71 86
Interest & Investment Income		 0.03 0.02 0.26 2.80 11 9.30 6.74 12 17 20 18
Other Income / (Expense), net		 4.59 0.85 1.35 8.29 9.52 4.43 61 13 3.72 3.94 -2.35
Income Tax Expense		 54 16 -53 -3.40 9.90 -40 46 33 13 -11 -47
Basic Earnings per Share		 ($0.05) $1.00 $0.84 $0.73 $0.59 $1.58 $2.00 $2.18 $0.85 ($0.09) ($6.74)
Weighted Average Basic Shares Outstanding		 68.99M 74.39M 76.90M 82.86M 85.64M 84.65M 84.70M 83.00M 80.09M 77.01M 76.67M
Diluted Earnings per Share		 ($0.05) $0.94 $0.82 $0.72 $0.58 $1.57 $1.98 $2.16 $0.84 ($0.09) ($6.74)
Weighted Average Diluted Shares Outstanding		 71.35M 79.19M 79.12M 84.00M 86.49M 85.23M 85.49M 83.52M 80.34M 77.01M 76.67M
Weighted Average Basic & Diluted Shares Outstanding		 70.40M 74.60M 77.10M 83.30M 84.44M 84.37M 83.24M 81.64M 78.22M 77.22M 77.94M

Quarterly Income Statements for Integra LifeSciences

This table shows Integra LifeSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 4.18 19 20 -3.28 -12 -11 19 -25 -484 -5.40 -1.70
Consolidated Net Income / (Loss)		 4.18 19 20 -3.28 -12 -11 19 -25 -484 -5.40 -1.70
Net Income / (Loss) Continuing Operations		 4.18 19 20 -3.28 -12 -11 19 -25 -484 -5.40 -1.70
Total Pre-Tax Income 		3.82 19 29 -5.23 -15 -20 23 -30 -531 -6.82 4.31
Total Operating Income		 13 27 36 3.96 -3.03 -8.15 36 -15 -513 12 23
Total Gross Profit		 207 218 226 207 226 200 249 194 209 207 221
Total Revenue		 381 382 397 369 418 381 443 383 416 402 435
Operating Revenue		 381 382 397 369 418 381 443 383 416 402 435
Total Cost of Revenue		 174 164 171 162 192 181 194 188 206 195 214
Operating Cost of Revenue		 174 164 171 162 192 181 194 188 206 195 214
Total Operating Expenses		 195 192 190 203 229 208 213 210 722 195 198
Selling, General & Admin Expense		 165 162 163 166 195 177 179 181 180 169 169
Research & Development Expense		 27 27 24 27 30 27 31 25 27 22 25
Amortization Expense		 3.03 3.21 3.03 10 3.71 3.76 3.72 3.70 3.75 3.73 3.77
Total Other Income / (Expense), net		 -8.68 -7.98 -7.19 -9.19 -12 -12 -13 -15 -18 -19 -19
Interest Expense		 12 13 14 14 19 19 19 19 21 23 24
Interest & Investment Income		 3.94 4.61 4.55 5.04 5.06 5.05 4.89 4.42 4.71 4.98 4.36
Other Income / (Expense), net		 -0.16 0.47 2.01 -0.61 1.44 2.11 1.01 -0.14 -1.95 -0.84 0.58
Income Tax Expense		 -0.36 -0.89 9.02 -1.95 -2.78 -9.67 3.11 -4.74 -47 -1.42 6.01
Basic Earnings per Share		 $0.05 $0.24 $0.26 ($0.04) ($0.16) ($0.14) $0.25 ($0.33) ($6.31) ($0.07) ($0.03)
Weighted Average Basic Shares Outstanding		 80.97M 79.69M 80.09M 77.74M 77.41M 76.45M 77.01M 76.46M 76.70M 76.75M 76.67M
Diluted Earnings per Share		 $0.05 $0.24 $0.26 ($0.04) ($0.16) ($0.14) $0.25 ($0.33) ($6.31) ($0.07) ($0.03)
Weighted Average Diluted Shares Outstanding		 81.15M 79.81M 80.34M 77.74M 77.41M 76.45M 77.01M 76.46M 76.70M 76.75M 76.67M
Weighted Average Basic & Diluted Shares Outstanding		 81.40M 78.18M 78.22M 78.80M 77.58M 77.16M 77.22M 77.71M 77.91M 77.89M 77.94M

Annual Cash Flow Statements for Integra LifeSciences

This table details how cash moves in and out of Integra LifeSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -24 54 73 -31 60 271 43 -57 -180 -30 -11
Net Cash From Operating Activities		 105 116 115 200 231 204 312 264 140 129 50
Net Cash From Continuing Operating Activities		 117 116 115 200 231 204 312 264 140 129 50
Net Income / (Loss) Continuing Operations		 6.85 75 65 61 50 134 169 181 68 -6.94 -516
Consolidated Net Income / (Loss)		 -3.52 75 65 61 50 134 169 181 68 -6.94 -516
Depreciation Expense		 59 73 89 111 109 116 120 118 124 141 152
Amortization Expense		 2.26 2.53 2.72 6.27 5.39 12 - 6.85 6.16 5.59 5.61
Non-Cash Adjustments To Reconcile Net Income		 60 -16 31 27 99 46 10 23 23 47 531
Changes in Operating Assets and Liabilities, net		 -11 -18 -73 -5.22 -32 -105 13 -64 -81 -58 -121
Net Cash From Investing Activities		 -372 -43 -1,221 -50 -163 -68 -161 -59 -94 -391 -108
Net Cash From Continuing Investing Activities		 -365 -43 -1,221 -50 -163 -68 -161 -59 -94 -391 -108
Purchase of Property, Plant & Equipment		 -33 -47 -44 -78 -70 -39 -48 -42 -67 -104 -81
Acquisitions		 -329 - -1,242 0.00 -96 -25 -304 -56 0.00 -288 -14
Purchase of Investments		 - - - 0.00 1.58 -7.84 0.00 4.91 -33 -49 -19
Sale and/or Maturity of Investments		 0.00 0.00 17 0.91 0.75 - 0.08 0.00 5.38 50 7.00
Net Cash From Financing Activities		 248 -15 1,169 -181 -8.77 122 -98 -252 -230 238 28
Net Cash From Continuing Financing Activities		 295 -15 1,169 -181 -8.77 122 -98 -252 -230 238 28
Repayment of Debt		 -470 -701 -136 -665 -246 -465 -126 -149 -118 -187 -674
Repurchase of Common Equity		 - - - 0.00 0.00 -100 0.00 -125 -275 -52 -0.22
Issuance of Debt		 545 680 1,307 171 237 747 26 41 165 487 721
Other Financing Activities, net		 0.72 5.63 -2.01 -37 0.43 -104 2.02 -19 -1.55 -9.04 -18
Other Net Changes in Cash		 - - 11 - 0.07 - - -11 3.89 -6.46 18

Quarterly Cash Flow Statements for Integra LifeSciences

This table details how cash moves in and out of Integra LifeSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 1.83 -35 2.67 316 -377 -0.08 31 -7.27 -21 14 2.86
Net Cash From Operating Activities		 28 27 59 16 40 22 51 -11 8.92 41 12
Net Cash From Continuing Operating Activities		 28 27 59 16 40 22 51 -11 8.92 41 12
Net Income / (Loss) Continuing Operations		 4.18 19 20 -3.28 -12 -11 19 -25 -484 -5.40 -1.70
Consolidated Net Income / (Loss)		 4.18 19 20 -3.28 -12 -11 19 -25 -484 -5.40 -1.70
Depreciation Expense		 31 31 31 31 37 36 38 37 38 39 38
Amortization Expense		 1.42 1.42 1.43 1.40 1.46 1.34 1.40 1.39 1.89 1.32 1.02
Non-Cash Adjustments To Reconcile Net Income		 5.68 5.93 6.64 13 14 3.66 17 2.11 516 5.27 7.06
Changes in Operating Assets and Liabilities, net		 -14 -31 -0.15 -26 0.44 -7.77 -24 -27 -63 1.20 -33
Net Cash From Investing Activities		 -16 -7.70 -57 -54 -322 -10 -4.25 -36 -22 -16 -35
Net Cash From Continuing Investing Activities		 -16 -7.70 -57 -54 -322 -10 -4.25 -36 -22 -16 -35
Purchase of Property, Plant & Equipment		 -16 -13 -25 -15 -30 -30 -30 -29 -20 -15 -17
Acquisitions		 - - - - - - -5.77 - - - -14
Purchase of Investments		 - 5.38 -33 -39 -10 - -4.13 -7.00 -1.50 -0.43 -10
Sale and/or Maturity of Investments		 - - - - - - 35 - - - 7.00
Net Cash From Financing Activities		 -11 -50 -6.89 359 -94 -20 -7.15 35 -21 -10 24
Net Cash From Continuing Financing Activities		 -11 -50 -6.89 359 -94 -20 -7.15 35 -21 -10 24
Repayment of Debt		 -17 -57 -25 -15 -91 -42 -40 -15 -20 -614 -25
Issuance of Debt		 5.00 132 18 371 59 22 35 54 13 604 50
Other Financing Activities, net		 1.01 0.44 -0.09 3.28 -12 -0.17 -0.14 -3.78 -14 -0.20 -0.14
Other Net Changes in Cash		 -0.21 -4.87 8.04 -4.96 -1.13 7.75 -8.12 4.53 13 -0.80 1.61

Annual Balance Sheets for Integra LifeSciences

This table presents Integra LifeSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1,774 1,808 3,211 3,108 3,303 3,615 3,782 3,890 3,782 4,037 3,602
Total Current Assets		 438 495 822 775 858 1,237 1,154 1,161 1,058 1,082 1,160
Cash & Equivalents		 48 102 175 139 199 470 513 457 276 246 235
Short-Term Investments		 - - - - - - - 0.00 33 27 29
Accounts Receivable		 132 148 252 266 275 226 232 263 259 272 279
Inventories, net		 211 217 296 280 316 310 317 325 390 429 493
Prepaid Expenses		 43 28 99 90 68 69 91 86 67 77 96
Other Current Assets		 - - - - - - - 31 33 30 28
Plant, Property, & Equipment, net		 205 222 269 300 337 288 312 311 340 406 444
Total Noncurrent Assets		 1,131 1,090 2,120 2,033 2,108 2,090 2,317 2,417 2,384 2,550 1,998
Goodwill		 512 511 938 926 954 932 1,013 1,039 1,055 1,097 615
Intangible Assets		 604 561 1,160 1,079 1,032 989 1,146 1,127 1,068 1,208 1,135
Noncurrent Deferred & Refundable Income Taxes		 6.93 6.94 6.25 6.81 13 74 57 46 46 35 70
Other Noncurrent Operating Assets		 7.49 12 16 20 109 95 101 205 214 211 178
Total Liabilities & Shareholders' Equity		 1,774 1,808 3,211 3,108 3,303 3,615 3,782 3,890 3,782 4,037 3,602
Total Liabilities		 1,023 968 2,249 1,732 1,887 2,100 2,098 2,085 2,194 2,492 2,559
Total Current Liabilities		 139 124 349 263 331 401 340 321 307 922 456
Short-Term Debt		 14 0.00 83 23 45 146 45 38 15 607 127
Accounts Payable		 35 29 94 76 113 55 62 102 92 83 96
Accrued Expenses		 39 35 88 85 77 94 120 80 101 122 130
Current Deferred & Payable Income Tax Liabilities		 - - - - - - - - - 0.00 3.65
Current Employee Benefit Liabilities		 45 53 73 76 79 76 93 79 75 86 74
Other Current Liabilities		 - - - - 12 13 20 22 24 25 25
Total Noncurrent Liabilities		 884 845 1,900 1,470 1,555 1,699 1,758 1,764 1,887 1,570 2,103
Long-Term Debt		 700 665 1,781 1,332 1,303 1,408 1,501 1,405 1,485 1,196 1,730
Capital Lease Obligations		 - - - - - - 90 157 167 167 163
Noncurrent Deferred & Payable Income Tax Liabilities		 155 149 65 58 37 16 46 63 35 61 5.66
Other Noncurrent Operating Liabilities		 29 31 54 80 216 275 120 139 200 146 204
Total Equity & Noncontrolling Interests		 751 840 962 1,376 1,417 1,515 1,685 1,804 1,588 1,545 1,043
Total Preferred & Common Equity		 751 840 962 1,376 1,417 1,515 1,685 1,804 1,588 1,545 1,043
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 751 840 962 1,376 1,417 1,515 1,685 1,804 1,588 1,545 1,043
Common Stock		 1,021 799 823 1,193 1,215 1,292 1,266 1,278 1,303 1,324 1,339
Retained Earnings		 146 220 285 348 399 532 699 879 947 940 423
Treasury Stock		 -367 -123 -122 -121 -120 -235 -234 -363 -647 -691 -689
Accumulated Other Comprehensive Income / (Loss)		 -48 -57 -24 -45 -76 -74 -45 10 -15 -28 -30

Quarterly Balance Sheets for Integra LifeSciences

This table presents Integra LifeSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 3,753 3,807 3,742 3,778 3,739 4,078 4,074 4,066 4,053 3,668 3,646
Total Current Assets		 1,137 1,196 1,029 1,051 1,027 1,416 1,112 1,100 1,107 1,143 1,144
Cash & Equivalents		 447 512 307 309 274 592 215 215 239 218 232
Short-Term Investments		 - - - - - 71 82 62 34 36 36
Accounts Receivable		 237 248 254 259 256 241 271 248 252 285 262
Inventories, net		 320 311 351 354 366 403 422 437 445 465 489
Prepaid Expenses		 102 123 117 129 131 73 94 86 104 103 94
Other Current Assets		 31 1.83 - - - 35 29 50 32 36 30
Plant, Property, & Equipment, net		 302 301 315 318 319 345 374 391 423 435 437
Total Noncurrent Assets		 2,313 2,310 2,398 2,409 2,393 2,317 2,589 2,575 2,523 2,090 2,066
Goodwill		 990 978 1,042 1,043 1,036 1,040 1,105 1,117 1,105 616 615
Intangible Assets		 1,082 1,054 1,109 1,094 1,067 1,023 1,220 1,210 1,188 1,188 1,160
Noncurrent Deferred & Refundable Income Taxes		 47 52 45 56 56 34 46 49 38 103 110
Other Noncurrent Operating Assets		 193 226 203 216 235 220 218 200 192 183 180
Total Liabilities & Shareholders' Equity		 3,753 3,807 3,742 3,778 3,739 4,078 4,074 4,066 4,053 3,668 3,646
Total Liabilities		 2,092 2,083 2,067 2,094 2,160 2,480 2,540 2,544 2,529 2,629 2,609
Total Current Liabilities		 296 304 282 377 356 302 328 913 918 930 364
Short-Term Debt		 51 56 0.00 96 85 19 24 602 613 613 39
Accounts Payable		 69 81 113 100 94 94 107 78 91 93 92
Accrued Expenses		 85 79 93 95 90 112 102 132 137 131 133
Current Deferred Revenue		 5.43 6.36 - - - - - 9.99 - - 11
Current Employee Benefit Liabilities		 70 69 54 65 64 53 70 76 52 67 75
Other Current Liabilities		 13 13 23 23 23 24 25 15 25 25 14
Total Noncurrent Liabilities		 1,796 1,778 1,785 1,717 1,804 2,178 2,212 1,632 1,610 1,699 2,245
Long-Term Debt		 1,498 1,487 1,440 1,333 1,420 1,837 1,801 1,205 1,231 1,227 1,792
Noncurrent Deferred & Payable Income Tax Liabilities		 61 70 62 71 74 31 87 69 58 60 58
Other Noncurrent Operating Liabilities		 237 221 127 153 142 140 155 358 160 253 394
Total Equity & Noncontrolling Interests		 1,661 1,724 1,675 1,683 1,579 1,598 1,534 1,522 1,524 1,039 1,038
Total Preferred & Common Equity		 1,661 1,724 1,675 1,683 1,579 1,598 1,534 1,522 1,524 1,039 1,038
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,661 1,724 1,675 1,683 1,579 1,598 1,534 1,522 1,524 1,039 1,038
Common Stock		 1,261 1,269 1,246 1,285 1,263 1,311 1,302 1,318 1,324 1,329 1,334
Retained Earnings		 776 826 903 908 927 944 931 920 915 431 425
Treasury Stock		 -363 -363 -482 -514 -613 -646 -681 -692 -690 -690 -690
Accumulated Other Comprehensive Income / (Loss)		 -13 -7.44 7.07 4.83 1.75 -11 -19 -25 -24 -31 -32

Annual Metrics And Ratios for Integra LifeSciences

This table displays calculated financial ratios and metrics derived from Integra LifeSciences' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 77,892,111.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 77,892,111.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -6.63
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 10.80% 12.39% 19.77% 23.92% 3.06% -9.60% 12.43% 0.99% -1.03% 4.47% 1.53%
EBITDA Growth		 24.86% 31.71% -27.99% 71.45% -7.68% 30.15% 33.20% -0.39% -34.99% -26.98% -289.15%
EBIT Growth		 24.95% 38.03% -60.28% 158.48% -13.42% 50.85% 65.81% -2.62% -54.19% -71.92% -1,632.13%
NOPAT Growth		 -83.37% 958.51% 167.83% -53.86% -33.39% 176.73% -28.32% 29.83% -53.79% -78.66% -1,836.55%
Net Income Growth		 -110.35% 2,218.90% -13.17% -6.09% -17.43% 166.71% 26.28% 6.79% -62.48% -110.25% -7,337.70%
EPS Growth		 -110.35% 2,218.90% -12.77% -12.20% -19.44% 170.69% 26.11% 9.09% -61.11% -110.71% -7,388.89%
Operating Cash Flow Growth		 25.48% 11.02% -1.60% 74.33% 15.90% -11.93% 53.28% -15.35% -47.08% -7.55% -61.06%
Free Cash Flow Firm Growth		 -162.76% 135.50% -1,035.49% 117.88% -41.70% 222.20% -161.03% 129.98% 58.00% -386.75% 135.24%
Invested Capital Growth		 27.88% -0.79% 89.03% -2.27% -0.98% -4.56% 14.66% 5.01% -0.11% 10.07% -13.66%
Revenue Q/Q Growth		 11.13% 1.48% 10.50% 1.01% 0.78% -0.47% 1.11% -0.48% -0.06% 2.91% -0.47%
EBITDA Q/Q Growth		 1.85% 9.58% -13.10% 11.57% 0.63% 5.78% 1.63% 4.12% -11.72% 2.96% -3.85%
EBIT Q/Q Growth		 -3.82% 16.43% -39.20% 24.82% 1.14% 12.21% 3.35% 3.85% -22.64% -4.23% -2.70%
NOPAT Q/Q Growth		 -43.89% 17.19% 244.04% -50.58% -17.25% 130.64% -24.43% 2.43% -24.94% -1.46% -2.62%
Net Income Q/Q Growth		 -163.99% 21.64% 33.12% -24.02% -16.36% 137.12% -21.88% 4.37% -32.83% -6.11% -4.27%
EPS Q/Q Growth		 -163.99% 21.64% 32.26% -23.40% -17.14% 134.33% -21.74% 4.85% -30.58% -12.50% -4.33%
Operating Cash Flow Q/Q Growth		 0.75% -14.10% 4.58% 18.48% 25.14% -4.19% -3.40% 6.46% -15.96% -5.83% -43.58%
Free Cash Flow Firm Q/Q Growth		 -52.85% 82.82% -695.62% 123.51% 21.95% 5.26% -73.87% -58.35% 197.97% -433.12% -13.91%
Invested Capital Q/Q Growth		 2.41% -0.07% 65.44% -0.20% -1.54% 2.77% 3.78% 6.99% -1.12% 6.27% 7.62%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 63.01% 64.81% 63.35% 61.19% 62.79% 62.03% 61.24% 62.29% 57.39% 54.77% 50.86%
EBITDA Margin		 16.46% 19.29% 11.60% 16.05% 14.37% 20.70% 24.52% 24.18% 15.89% 11.10% -20.69%
Operating Margin		 9.02% 11.63% 3.77% 7.54% 6.18% 11.03% 12.79% 15.34% 7.23% 1.76% -30.17%
EBIT Margin		 9.54% 11.71% 3.88% 8.10% 6.81% 11.36% 16.75% 16.15% 7.48% 2.01% -30.31%
Profit (Net Income) Margin		 -0.40% 7.52% 5.45% 4.13% 3.31% 9.76% 10.96% 11.59% 4.39% -0.43% -31.58%
Tax Burden Percent		 -5.80% 82.48% 568.67% 105.92% 83.52% 143.17% 78.76% 84.41% 83.56% 38.08% 91.65%
Interest Burden Percent		 72.08% 77.81% 24.67% 48.12% 58.19% 60.02% 83.10% 85.02% 70.35% -56.37% 113.67%
Effective Tax Rate		 88.71% 17.52% -468.67% -5.92% 16.48% -43.17% 21.24% 15.59% 16.44% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.71% 6.76% 12.57% 4.49% 3.04% 8.64% 5.91% 7.01% 3.16% 0.64% -11.43%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1.64% 3.40% -4.31% 0.58% 0.66% 0.69% 7.25% 5.14% 1.13% -1.11% -21.35%
Return on Net Nonoperating Assets (RNNOA)		 -1.20% 2.62% -5.38% 0.72% 0.56% 0.49% 4.66% 3.34% 0.83% -1.09% -28.47%
Return on Equity (ROE)		 -0.48% 9.37% 7.19% 5.20% 3.60% 9.13% 10.57% 10.35% 3.99% -0.44% -39.90%
Cash Return on Invested Capital (CROIC)		 -23.76% 7.54% -49.03% 6.78% 4.02% 13.31% -7.75% 2.12% 3.27% -8.94% 3.23%
Operating Return on Assets (OROA)		 5.01% 6.49% 1.84% 3.78% 3.22% 4.50% 6.98% 6.56% 3.00% 0.83% -12.98%
Return on Assets (ROA)		 -0.21% 4.16% 2.58% 1.92% 1.57% 3.87% 4.57% 4.71% 1.77% -0.18% -13.52%
Return on Common Equity (ROCE)		 -0.48% 9.37% 7.19% 5.20% 3.60% 9.13% 10.57% 10.35% 3.99% -0.44% -39.90%
Return on Equity Simple (ROE_SIMPLE)		 -0.47% 8.88% 6.73% 4.42% 3.54% 8.84% 10.04% 10.01% 4.27% -0.45% 0.00%
Net Operating Profit after Tax (NOPAT)		 8.99 95 255 118 78 217 155 202 93 20 -345
NOPAT Margin		 1.02% 9.59% 21.44% 7.98% 5.16% 15.80% 10.07% 12.95% 6.05% 1.23% -21.12%
Net Nonoperating Expense Percent (NNEP)		 2.35% 3.36% 16.88% 3.91% 2.38% 7.95% -1.34% 1.86% 2.03% 1.76% 9.91%
Return On Investment Capital (ROIC_SIMPLE)		 0.61% 6.32% 9.02% 4.31% 2.83% 7.06% 4.68% 5.92% 2.86% 0.57% -11.28%
Cost of Revenue to Revenue		 36.99% 35.19% 36.65% 38.81% 37.21% 37.97% 38.76% 37.71% 42.61% 45.23% 49.14%
SG&A Expenses to Revenue		 47.10% 45.93% 52.52% 46.91% 45.31% 43.34% 41.33% 39.57% 42.60% 44.52% 42.79%
R&D to Revenue		 5.77% 5.86% 5.34% 5.30% 9.52% 5.64% 6.03% 6.50% 6.76% 7.16% 6.05%
Operating Expenses to Revenue		 53.99% 53.19% 59.58% 53.65% 56.61% 51.00% 48.46% 46.95% 50.16% 53.00% 81.03%
Earnings before Interest and Taxes (EBIT)		 84 116 46 119 103 156 258 252 115 32 -496
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 145 191 138 236 218 284 378 377 245 179 -338
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.34 3.82 3.90 2.79 3.53 3.61 3.37 2.60 2.14 1.13 0.93
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.84 3.23 3.16 2.61 3.30 3.99 3.68 3.01 2.21 1.09 0.59
Price to Earnings (P/E)		 0.00 43.01 58.01 63.18 99.68 40.86 33.56 25.94 50.26 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 2.32% 1.72% 1.58% 1.00% 2.45% 2.98% 3.86% 1.99% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.24 2.69 2.05 1.95 2.40 2.68 2.42 1.98 1.62 1.06 0.97
Enterprise Value to Revenue (EV/Rev)		 3.59 3.80 4.58 3.43 4.05 4.78 4.41 3.74 3.09 2.14 1.67
Enterprise Value to EBITDA (EV/EBITDA)		 21.81 19.70 39.51 21.40 28.21 23.09 17.97 15.47 19.44 19.27 0.00
Enterprise Value to EBIT (EV/EBIT)		 37.65 32.45 117.99 42.39 59.58 42.07 26.31 23.16 41.32 106.52 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 352.61 39.63 21.37 43.01 78.58 30.25 43.76 28.89 51.10 173.30 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 30.22 32.39 47.54 25.33 26.59 32.16 21.76 22.03 34.02 26.64 54.04
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 35.49 0.00 28.46 59.40 19.64 0.00 95.42 49.36 0.00 27.93
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.95 0.79 1.94 0.98 0.95 1.03 0.97 0.89 1.05 1.27 1.94
Long-Term Debt to Equity		 0.93 0.79 1.85 0.97 0.92 0.93 0.94 0.87 1.04 0.88 1.81
Financial Leverage		 0.73 0.77 1.25 1.24 0.85 0.71 0.64 0.65 0.74 0.97 1.33
Leverage Ratio		 2.31 2.25 2.79 2.70 2.30 2.36 2.31 2.20 2.26 2.50 2.95
Compound Leverage Factor		 1.66 1.75 0.69 1.30 1.34 1.42 1.92 1.87 1.59 -1.41 3.35
Debt to Total Capital		 48.74% 44.20% 65.95% 49.60% 48.76% 50.65% 49.27% 47.01% 51.21% 56.04% 65.93%
Short-Term Debt to Total Capital		 0.98% 0.00% 2.93% 0.82% 1.63% 4.76% 1.35% 1.12% 0.45% 17.27% 4.13%
Long-Term Debt to Total Capital		 47.76% 44.20% 63.02% 48.78% 47.13% 45.88% 47.92% 45.89% 50.76% 38.77% 61.80%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 51.26% 55.80% 34.05% 50.40% 51.24% 49.35% 50.73% 52.99% 48.79% 43.96% 34.07%
Debt to EBITDA		 4.92 3.47 13.52 5.73 6.18 5.48 4.33 4.25 6.80 11.02 -5.97
Net Debt to EBITDA		 4.56 2.94 12.26 5.14 5.27 3.82 2.97 3.04 5.54 9.49 -5.19
Long-Term Debt to EBITDA		 4.82 3.47 12.92 5.64 5.97 4.96 4.21 4.15 6.74 7.62 -5.59
Debt to NOPAT		 79.50 6.99 7.32 11.52 17.21 7.17 10.54 7.94 17.88 99.06 -5.85
Net Debt to NOPAT		 73.69 5.92 6.63 10.34 14.67 5.00 7.23 5.67 14.56 85.30 -5.08
Long-Term Debt to NOPAT		 77.90 6.99 6.99 11.33 16.64 6.50 10.25 7.75 17.73 68.53 -5.48
Altman Z-Score		 2.44 3.17 1.72 2.29 2.51 2.57 2.77 2.54 2.03 1.22 0.63
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.15 4.01 2.36 2.95 2.59 3.09 3.39 3.62 3.45 1.17 2.54
Quick Ratio		 1.30 2.02 1.22 1.54 1.43 1.73 2.19 2.24 1.85 0.59 1.19
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -299 106 -994 178 104 334 -204 61 96 -277 97
Operating Cash Flow to CapEx		 327.92% 247.61% 265.09% 258.26% 333.00% 578.53% 650.63% 847.71% 209.31% 123.91% 61.87%
Free Cash Flow to Firm to Interest Expense		 -12.72 4.12 -28.38 2.75 1.92 4.66 -4.04 1.23 1.88 -3.92 1.13
Operating Cash Flow to Interest Expense		 4.46 4.51 3.27 3.09 4.29 2.85 6.20 5.33 2.72 1.83 0.58
Operating Cash Flow Less CapEx to Interest Expense		 3.10 2.69 2.04 1.89 3.00 2.36 5.25 4.70 1.42 0.35 -0.36
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.53 0.55 0.47 0.47 0.47 0.40 0.42 0.41 0.40 0.41 0.43
Accounts Receivable Turnover		 7.28 7.08 5.94 5.69 5.61 5.48 6.75 6.29 5.90 6.06 5.93
Inventory Turnover		 1.63 1.63 1.70 1.98 1.89 1.66 1.91 1.83 1.84 1.78 1.74
Fixed Asset Turnover		 4.43 4.64 4.83 5.17 4.76 4.39 5.15 5.00 4.73 4.32 3.85
Accounts Payable Turnover		 10.26 10.94 7.08 6.72 5.97 6.21 10.27 7.17 6.76 8.33 9.02
Days Sales Outstanding (DSO)		 50.17 51.59 61.43 64.15 65.06 66.63 54.11 58.03 61.89 60.25 61.52
Days Inventory Outstanding (DIO)		 223.87 224.12 215.22 184.16 192.75 219.41 191.57 199.47 198.44 205.11 209.34
Days Payable Outstanding (DPO)		 35.57 33.37 51.55 54.29 61.13 58.76 35.55 50.94 54.02 43.80 40.47
Cash Conversion Cycle (CCC)		 238.47 242.33 225.10 194.01 196.69 227.27 210.13 206.56 206.31 221.56 230.39
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1,414 1,403 2,651 2,591 2,566 2,449 2,808 2,948 2,945 3,242 2,799
Invested Capital Turnover		 0.70 0.70 0.59 0.56 0.59 0.55 0.59 0.54 0.52 0.52 0.54
Increase / (Decrease) in Invested Capital		 308 -11 1,249 -60 -25 -117 359 141 -3.29 297 -443
Enterprise Value (EV)		 3,169 3,770 5,445 5,057 6,153 6,555 6,797 5,827 4,762 3,447 2,723
Market Capitalization		 2,507 3,207 3,756 3,842 5,004 5,471 5,674 4,683 3,405 1,750 967
Book Value per Share		 $20.32 $22.46 $12.26 $16.15 $16.50 $17.98 $19.89 $21.60 $20.31 $20.03 $13.40
Tangible Book Value per Share		 ($9.86) ($6.21) ($14.47) ($7.40) ($6.63) ($4.83) ($5.60) ($4.32) ($6.85) ($9.84) ($9.07)
Total Capital		 1,466 1,505 2,826 2,730 2,765 3,069 3,321 3,405 3,254 3,515 3,063
Total Debt		 714 665 1,864 1,354 1,348 1,554 1,637 1,601 1,666 1,970 2,019
Total Long-Term Debt		 700 665 1,781 1,332 1,303 1,408 1,592 1,563 1,652 1,363 1,893
Net Debt		 662 563 1,689 1,215 1,149 1,084 1,123 1,144 1,357 1,696 1,755
Capital Expenditures (CapEx)		 32 47 43 77 70 35 48 31 67 104 81
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 262 270 381 396 373 512 345 422 456 493 566
Debt-free Net Working Capital (DFNWC)		 314 372 556 535 572 982 859 879 766 767 830
Net Working Capital (NWC)		 299 372 473 513 527 836 814 841 751 160 704
Net Nonoperating Expense (NNE)		 13 21 190 57 28 83 -14 21 25 27 171
Net Nonoperating Obligations (NNO)		 662 563 1,689 1,215 1,149 934 1,123 1,144 1,357 1,696 1,755
Total Depreciation and Amortization (D&A)		 61 75 92 117 115 128 120 125 130 146 157
Debt-free, Cash-free Net Working Capital to Revenue		 29.63% 27.17% 32.07% 26.91% 24.58% 37.34% 22.38% 27.10% 29.61% 30.62% 34.64%
Debt-free Net Working Capital to Revenue		 35.54% 37.45% 46.79% 36.34% 37.68% 71.61% 55.67% 56.41% 49.66% 47.60% 50.76%
Net Working Capital to Revenue		 33.91% 37.45% 39.83% 34.81% 34.72% 60.95% 52.75% 53.96% 48.72% 9.91% 43.02%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.05) $1.00 $0.84 $0.73 $0.59 $1.58 $2.00 $2.18 $0.85 ($0.09) ($6.74)
Adjusted Weighted Average Basic Shares Outstanding		 68.99M 74.39M 76.90M 82.86M 85.64M 84.65M 84.70M 83.00M 80.09M 77.01M 76.67M
Adjusted Diluted Earnings per Share		 ($0.05) $0.94 $0.82 $0.72 $0.58 $1.57 $1.98 $2.16 $0.84 ($0.09) ($6.74)
Adjusted Weighted Average Diluted Shares Outstanding		 71.35M 79.19M 79.12M 84.00M 86.49M 85.23M 85.49M 83.52M 80.34M 77.01M 76.67M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 74.00M 74.82M 78.49M 85.23M 84.44M 84.37M 83.24M 81.64M 78.22M 77.22M 77.94M
Normalized Net Operating Profit after Tax (NOPAT)		 56 95 31 78 78 106 155 202 93 20 13
Normalized NOPAT Margin		 6.31% 9.59% 2.64% 5.28% 5.16% 7.72% 10.07% 12.95% 6.05% 1.23% 0.77%
Pre Tax Income Margin		 6.87% 9.11% 0.96% 3.90% 3.96% 6.82% 13.92% 13.73% 5.26% -1.13% -34.46%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 3.58 4.50 1.32 1.84 1.91 2.18 5.13 5.07 2.24 0.46 -5.75
NOPAT to Interest Expense		 0.38 3.69 7.28 1.82 1.45 3.03 3.08 4.07 1.81 0.28 -4.00
EBIT Less CapEx to Interest Expense		 2.22 2.68 0.08 0.65 0.63 1.68 4.17 4.44 0.94 -1.02 -6.69
NOPAT Less CapEx to Interest Expense		 -0.98 1.86 6.04 0.62 0.16 2.54 2.13 3.44 0.51 -1.20 -4.95
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 74.69% 0.00% 69.23% 405.96% -755.63% -0.04%

Quarterly Metrics And Ratios for Integra LifeSciences

This table displays calculated financial ratios and metrics derived from Integra LifeSciences' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 77,892,111.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 77,892,111.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.02
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -4.16% -0.72% -0.25% -3.14% 9.68% -0.42% 11.49% 3.74% -0.61% 5.57% -1.74%
EBITDA Growth		 -52.11% -40.70% -31.57% -50.12% -17.83% -47.06% 7.30% -35.07% -1,396.32% 62.38% -16.60%
EBIT Growth		 -80.03% -60.40% -46.99% -91.12% -112.89% -122.31% -3.75% -566.34% -32,225.38% 280.84% -35.52%
NOPAT Growth		 -73.68% -49.55% -55.71% -90.63% -115.50% -120.48% 23.98% -490.94% -16,825.52% 244.31% -129.66%
Net Income Growth		 -90.66% -60.94% -62.54% -113.54% -396.41% -154.85% -2.02% -670.89% -3,803.19% 49.47% -108.77%
EPS Growth		 -90.74% -60.00% -58.73% -113.79% -420.00% -158.33% -3.85% -725.00% -3,843.75% 50.00% -112.00%
Operating Cash Flow Growth		 -57.46% -60.81% -31.15% -39.76% 42.87% -16.01% -13.63% -171.45% -77.92% 81.93% -76.71%
Free Cash Flow Firm Growth		 -2,266.04% -4,040.08% 133.15% 103.36% -47.53% 60.07% -1,047.17% -5,159.43% 132.61% 688.85% 263.16%
Invested Capital Growth		 7.16% 8.08% -0.11% -0.11% 9.10% 2.42% 10.07% 9.95% -13.84% -14.74% -13.66%
Revenue Q/Q Growth		 0.11% 0.30% 3.82% -7.09% 13.37% -8.93% 16.23% -13.55% 8.61% -3.26% 8.17%
EBITDA Q/Q Growth		 -37.01% 32.38% 19.38% -49.89% 3.76% -14.70% 141.92% -69.67% -2,171.51% 110.68% 24.25%
EBIT Q/Q Growth		 -67.31% 119.16% 40.63% -91.19% -147.47% -279.27% 706.67% -142.70% -3,190.20% 102.12% 116.33%
NOPAT Q/Q Growth		 -53.78% 103.65% -11.08% -88.80% -176.41% -169.07% 638.42% -135.32% -3,208.21% 102.29% -210.65%
Net Income Q/Q Growth		 -82.73% 365.99% 1.73% -116.54% -277.99% 13.76% 281.71% -230.15% -1,813.86% 98.88% 68.47%
EPS Q/Q Growth		 -82.76% 380.00% 8.33% -115.38% -300.00% 12.50% 278.57% -232.00% -1,812.12% 98.89% 57.14%
Operating Cash Flow Q/Q Growth		 8.12% -5.34% 119.46% -73.18% 156.42% -44.35% 125.66% -122.19% 179.23% 358.64% -71.11%
Free Cash Flow Firm Q/Q Growth		 -2.56% -5.77% 114.41% -78.48% -4,598.95% 71.37% -241.77% -14.93% 129.00% 416.91% -5.30%
Invested Capital Q/Q Growth		 -0.06% 0.54% -1.12% 0.53% 9.16% -5.62% 6.27% 0.43% -14.47% -6.60% 7.62%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 54.30% 57.10% 57.05% 56.07% 54.02% 52.58% 56.27% 50.81% 50.37% 51.48% 50.78%
EBITDA Margin		 11.70% 15.44% 17.75% 9.57% 8.76% 8.21% 17.08% 5.99% -114.30% 12.62% 14.50%
Operating Margin		 3.28% 6.95% 9.08% 1.07% -0.72% -2.14% 8.05% -4.05% -123.36% 2.93% 5.30%
EBIT Margin		 3.24% 7.08% 9.59% 0.91% -0.38% -1.59% 8.28% -4.09% -123.82% 2.72% 5.43%
Profit (Net Income) Margin		 1.10% 5.10% 5.00% -0.89% -2.97% -2.81% 4.39% -6.61% -116.47% -1.34% -0.39%
Tax Burden Percent		 109.41% 104.77% 68.73% 62.73% 81.67% 52.52% 86.22% 84.21% 91.17% 79.19% -39.54%
Interest Burden Percent		 30.97% 68.76% 75.82% -155.93% 953.83% 337.23% 61.53% 192.03% 103.17% -62.50% 18.25%
Effective Tax Rate		 -9.41% -4.77% 31.27% 0.00% 0.00% 0.00% 13.78% 0.00% 0.00% 0.00% 139.54%
Return on Invested Capital (ROIC)		 1.94% 3.92% 3.26% 0.39% -0.26% -0.78% 3.61% -1.48% -46.55% 1.19% -1.13%
ROIC Less NNEP Spread (ROIC-NNEP)		 1.14% 3.23% 2.87% -0.07% -0.95% -1.12% 2.87% -2.42% -53.82% 0.31% -0.70%
Return on Net Nonoperating Assets (RNNOA)		 0.81% 2.38% 2.12% -0.06% -0.88% -1.06% 2.80% -2.39% -72.04% 0.37% -0.94%
Return on Equity (ROE)		 2.75% 6.30% 5.38% 0.33% -1.13% -1.83% 6.41% -3.88% -118.59% 1.56% -2.07%
Cash Return on Invested Capital (CROIC)		 -1.59% -3.43% 3.27% 2.44% -6.91% -1.72% -8.94% -9.28% 3.22% 4.01% 3.23%
Operating Return on Assets (OROA)		 1.33% 2.89% 3.85% 0.36% -0.15% -0.64% 3.41% -1.63% -51.87% 1.16% 2.33%
Return on Assets (ROA)		 0.45% 2.08% 2.01% -0.35% -1.18% -1.13% 1.81% -2.64% -48.79% -0.57% -0.17%
Return on Common Equity (ROCE)		 2.75% 6.30% 5.38% 0.33% -1.13% -1.83% 6.41% -3.88% -118.59% 1.56% -2.07%
Return on Equity Simple (ROE_SIMPLE)		 7.80% 6.39% 0.00% 2.52% 1.54% -0.43% 0.00% -1.90% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 14 28 25 2.77 -2.12 -5.71 31 -11 -359 8.23 -9.11
NOPAT Margin		 3.59% 7.29% 6.24% 0.75% -0.51% -1.50% 6.94% -2.83% -86.35% 2.05% -2.09%
Net Nonoperating Expense Percent (NNEP)		 0.80% 0.69% 0.40% 0.46% 0.69% 0.34% 0.74% 0.93% 7.27% 0.88% -0.43%
Return On Investment Capital (ROIC_SIMPLE)		 0.42% 0.86% 0.76% 0.08% -0.06% -0.17% 0.87% -0.31% -11.81% 0.29% -0.30%
Cost of Revenue to Revenue		 45.70% 42.90% 42.95% 43.93% 45.98% 47.42% 43.73% 49.19% 49.63% 48.52% 49.22%
SG&A Expenses to Revenue		 43.25% 42.35% 41.09% 44.95% 46.74% 46.53% 40.33% 47.43% 43.28% 42.04% 38.92%
R&D to Revenue		 6.97% 6.95% 6.12% 7.31% 7.12% 7.20% 7.05% 6.46% 6.50% 5.59% 5.70%
Operating Expenses to Revenue		 51.02% 50.14% 47.97% 55.00% 54.75% 54.72% 48.22% 54.86% 173.72% 48.56% 45.48%
Earnings before Interest and Taxes (EBIT)		 12 27 38 3.35 -1.59 -6.04 37 -16 -515 11 24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 45 59 70 35 37 31 76 23 -475 51 63
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.00 1.97 2.14 1.73 1.50 0.93 1.13 1.11 0.92 1.08 0.93
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.18 2.02 2.21 1.81 1.47 0.90 1.09 1.05 0.59 0.68 0.59
Price to Earnings (P/E)		 25.66 30.83 50.26 68.88 97.10 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 3.90% 3.24% 1.99% 1.45% 1.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.57 1.51 1.62 1.40 1.24 0.96 1.06 1.05 0.97 1.03 0.97
Enterprise Value to Revenue (EV/Rev)		 3.01 2.92 3.09 2.70 2.55 1.88 2.14 2.11 1.66 1.63 1.67
Enterprise Value to EBITDA (EV/EBITDA)		 14.62 16.25 19.44 19.74 19.82 16.92 19.27 20.60 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 24.43 30.26 41.32 51.15 59.72 86.98 106.52 256.70 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 30.51 36.31 51.10 59.83 71.87 145.61 173.30 547.41 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 22.34 27.07 34.02 31.91 28.19 21.39 26.64 33.50 38.08 30.01 54.04
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 49.36 57.13 0.00 0.00 0.00 0.00 27.83 23.66 27.93
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.94 1.06 1.05 1.27 1.30 1.19 1.27 1.32 1.93 1.76 1.94
Long-Term Debt to Equity		 0.89 1.01 1.04 1.26 1.28 0.79 0.88 0.91 1.33 1.73 1.81
Financial Leverage		 0.71 0.74 0.74 0.81 0.93 0.94 0.97 0.99 1.34 1.21 1.33
Leverage Ratio		 2.25 2.28 2.26 2.39 2.44 2.52 2.50 2.60 3.01 3.01 2.95
Compound Leverage Factor		 0.70 1.57 1.71 -3.73 23.28 8.49 1.54 5.00 3.10 -1.88 0.54
Debt to Total Capital		 48.55% 51.44% 51.21% 55.91% 56.53% 54.28% 56.04% 56.81% 65.81% 63.83% 65.93%
Short-Term Debt to Total Capital		 2.92% 2.63% 0.45% 0.53% 0.69% 18.07% 17.27% 17.36% 20.19% 1.35% 4.13%
Long-Term Debt to Total Capital		 45.63% 48.82% 50.76% 55.37% 55.84% 36.21% 38.77% 39.45% 45.63% 62.48% 61.80%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 51.45% 48.56% 48.79% 44.09% 43.47% 45.72% 43.96% 43.19% 34.19% 36.17% 34.07%
Debt to EBITDA		 5.00 6.03 6.80 9.67 9.90 10.40 11.02 12.04 -5.79 -5.62 -5.97
Net Debt to EBITDA		 4.02 5.04 5.54 6.51 8.43 8.80 9.49 10.40 -5.06 -4.80 -5.19
Long-Term Debt to EBITDA		 4.70 5.72 6.74 9.58 9.78 6.94 7.62 8.36 -4.02 -5.50 -5.59
Debt to NOPAT		 10.43 13.48 17.88 29.32 35.89 89.51 99.06 319.99 -5.71 -5.44 -5.85
Net Debt to NOPAT		 8.40 11.27 14.56 19.72 30.55 75.76 85.30 276.37 -4.98 -4.64 -5.08
Long-Term Debt to NOPAT		 9.80 12.79 17.73 29.04 35.46 59.71 68.53 222.21 -3.96 -5.33 -5.48
Altman Z-Score		 1.94 1.86 1.96 1.70 1.48 1.08 1.22 1.16 0.43 1.14 1.10
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.78 2.89 3.45 4.68 3.39 1.20 1.17 1.21 1.23 3.14 2.54
Quick Ratio		 1.50 1.49 1.85 2.99 1.73 0.58 0.59 0.57 0.58 1.46 1.19
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -184 -195 28 6.04 -272 -78 -266 -306 89 458 434
Operating Cash Flow to CapEx		 181.88% 204.69% 239.45% 101.88% 136.00% 75.85% 171.42% -38.92% 44.27% 269.90% 68.64%
Free Cash Flow to Firm to Interest Expense		 -14.77 -14.91 2.04 0.44 -14.57 -4.02 -14.00 -16.24 4.21 20.16 18.32
Operating Cash Flow to Interest Expense		 2.27 2.05 4.27 1.16 2.17 1.16 2.67 -0.60 0.42 1.80 0.50
Operating Cash Flow Less CapEx to Interest Expense		 1.02 1.05 2.49 0.02 0.57 -0.37 1.11 -2.14 -0.53 1.13 -0.23
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.41 0.41 0.40 0.39 0.40 0.40 0.41 0.40 0.42 0.43 0.43
Accounts Receivable Turnover		 6.23 6.11 5.90 6.18 5.91 6.20 6.06 6.58 5.84 6.44 5.93
Inventory Turnover		 1.83 1.87 1.84 1.78 1.78 1.76 1.78 1.78 1.73 1.69 1.74
Fixed Asset Turnover		 4.99 4.98 4.73 4.63 4.53 4.41 4.32 4.23 4.01 3.97 3.85
Accounts Payable Turnover		 7.31 7.28 6.76 6.48 6.65 8.24 8.33 8.13 7.67 9.22 9.02
Days Sales Outstanding (DSO)		 58.58 59.69 61.89 59.07 61.72 58.84 60.25 55.45 62.53 56.70 61.52
Days Inventory Outstanding (DIO)		 198.99 194.90 198.44 205.29 205.59 207.79 205.11 205.28 210.57 215.80 209.34
Days Payable Outstanding (DPO)		 49.94 50.15 54.02 56.36 54.90 44.29 43.80 44.91 47.56 39.61 40.47
Cash Conversion Cycle (CCC)		 207.64 204.44 206.31 208.01 212.41 222.33 221.56 215.82 225.54 232.89 230.39
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2,963 2,979 2,945 2,961 3,232 3,051 3,242 3,256 2,785 2,601 2,799
Invested Capital Turnover		 0.54 0.54 0.52 0.52 0.51 0.52 0.52 0.52 0.54 0.58 0.54
Increase / (Decrease) in Invested Capital		 198 223 -3.29 -3.26 270 72 297 295 -447 -450 -443
Enterprise Value (EV)		 4,648 4,508 4,762 4,134 3,994 2,939 3,447 3,430 2,700 2,680 2,723
Market Capitalization		 3,369 3,109 3,405 2,771 2,296 1,410 1,750 1,698 954 1,116 967
Book Value per Share		 $20.55 $19.40 $20.31 $20.56 $19.47 $19.61 $20.03 $19.74 $13.37 $13.32 $13.40
Tangible Book Value per Share		 ($5.54) ($6.44) ($6.85) ($5.98) ($10.03) ($10.37) ($9.84) ($9.96) ($9.85) ($9.47) ($9.07)
Total Capital		 3,272 3,252 3,254 3,624 3,529 3,328 3,515 3,529 3,038 2,869 3,063
Total Debt		 1,589 1,673 1,666 2,026 1,995 1,807 1,970 2,005 2,000 1,831 2,019
Total Long-Term Debt		 1,493 1,588 1,652 2,007 1,971 1,205 1,363 1,392 1,386 1,792 1,893
Net Debt		 1,279 1,399 1,357 1,363 1,698 1,529 1,696 1,731 1,746 1,563 1,755
Capital Expenditures (CapEx)		 16 13 25 15 30 30 30 29 20 15 17
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 460 483 456 470 511 511 493 528 573 550 566
Debt-free Net Working Capital (DFNWC)		 769 757 766 1,133 808 788 767 801 826 818 830
Net Working Capital (NWC)		 674 672 751 1,113 784 187 160 189 213 780 704
Net Nonoperating Expense (NNE)		 9.50 8.36 4.94 6.06 10 4.99 11 14 125 14 -7.41
Net Nonoperating Obligations (NNO)		 1,279 1,399 1,357 1,363 1,698 1,529 1,696 1,731 1,746 1,563 1,755
Total Depreciation and Amortization (D&A)		 32 32 32 32 38 37 39 39 40 40 39
Debt-free, Cash-free Net Working Capital to Revenue		 29.78% 31.32% 29.61% 30.70% 32.64% 32.64% 30.62% 32.52% 35.32% 33.50% 34.64%
Debt-free Net Working Capital to Revenue		 49.79% 49.07% 49.66% 74.05% 51.59% 50.38% 47.60% 49.34% 50.96% 49.80% 50.76%
Net Working Capital to Revenue		 43.60% 43.53% 48.72% 72.78% 50.05% 11.95% 9.91% 11.62% 13.14% 47.45% 43.02%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.05 $0.24 $0.26 ($0.04) ($0.16) ($0.14) $0.25 ($0.33) ($6.31) ($0.07) ($0.03)
Adjusted Weighted Average Basic Shares Outstanding		 80.97M 79.69M 80.09M 77.74M 77.41M 76.45M 77.01M 76.46M 76.70M 76.75M 76.67M
Adjusted Diluted Earnings per Share		 $0.05 $0.24 $0.26 ($0.04) ($0.16) ($0.14) $0.25 ($0.33) ($6.31) ($0.07) ($0.03)
Adjusted Weighted Average Diluted Shares Outstanding		 81.15M 79.81M 80.34M 77.74M 77.41M 76.45M 77.01M 76.46M 76.70M 76.75M 76.67M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 81.40M 78.18M 78.22M 78.80M 77.58M 77.16M 77.22M 77.71M 77.91M 77.89M 77.94M
Normalized Net Operating Profit after Tax (NOPAT)		 8.75 19 25 2.77 -2.12 -5.71 31 -11 -0.92 8.23 16
Normalized NOPAT Margin		 2.30% 4.87% 6.24% 0.75% -0.51% -1.50% 6.94% -2.83% -0.22% 2.05% 3.71%
Pre Tax Income Margin		 1.00% 4.87% 7.27% -1.42% -3.63% -5.35% 5.09% -7.85% -127.75% -1.70% 0.99%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.99 2.07 2.77 0.25 -0.09 -0.31 1.93 -0.83 -24.46 0.48 1.00
NOPAT to Interest Expense		 1.10 2.13 1.80 0.20 -0.11 -0.29 1.62 -0.58 -17.06 0.36 -0.38
EBIT Less CapEx to Interest Expense		 -0.26 1.07 0.98 -0.89 -1.68 -1.84 0.37 -2.37 -25.41 -0.19 0.27
NOPAT Less CapEx to Interest Expense		 -0.15 1.13 0.02 -0.93 -1.71 -1.82 0.06 -2.11 -18.01 -0.30 -1.11
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 114.27% 272.67% 405.96% 310.68% 740.02% -764.06% -755.63% 0.00% -0.54% -0.54% -0.04%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways for Integra LifeSciences (IART) based on the latest quarterly data and observed trends across the last four years. Positive items are shown first, followed by neutral items, then negative items.

  • Operating cash flow from continuing activities in Q4 2025 was $11.82 million, indicating the business generated cash from core operations despite a quarterly net loss.
  • Net cash from financing activities in Q4 2025 was $24.34 million, aided by a debt issuance of about $49.70 million, which helped bolster liquidity.
  • Revenue remained around $435 million for Q4 2025 (approximately $434.93 million), a modest decline versus Q4 2024's about $442.65 million, suggesting relatively stable demand on a quarterly basis.
  • Total operating expenses in Q4 2025 were about $197.83 million, down modestly from Q4 2024’s about $213.45 million, indicating some cost containment.
  • Gross margin declined to about 50.7% in Q4 2025 from about 56.3% in Q4 2024, signaling pressure on profitability per dollar of revenue.
  • Net income attributable to common shareholders was negative $1.70 million in Q4 2025, reversing the prior year’s positive quarterly result of roughly $19.43 million.
  • Long-term debt rose to about $1.79 billion by Q3 2025, increasing leverage and adding interest burden relative to earlier periods.
  • Investing cash outflows were meaningful in Q4 2025, with net cash used for investing activities around $34.9 million (PPE additions and investments), contributing to negative quarterly free cash flow from investing activities.
05/05/26 03:09 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Integra LifeSciences' Financials

When does Integra LifeSciences' financial year end?

According to the most recent income statement we have on file, Integra LifeSciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Integra LifeSciences' net income changed over the last 10 years?

Integra LifeSciences' net income appears to be on a downward trend, with a most recent value of -$516.47 million in 2025, rising from -$3.52 million in 2015. The previous period was -$6.94 million in 2024. Find out what analysts predict for Integra LifeSciences in the coming months.

What is Integra LifeSciences' operating income?
Integra LifeSciences' total operating income in 2025 was -$493.37 million, based on the following breakdown:
  • Total Gross Profit: $831.62 million
  • Total Operating Expenses: $1.32 billion
How has Integra LifeSciences' revenue changed over the last 10 years?

Over the last 10 years, Integra LifeSciences' total revenue changed from $882.73 million in 2015 to $1.64 billion in 2025, a change of 85.2%.

How much debt does Integra LifeSciences have?

Integra LifeSciences' total liabilities were at $2.56 billion at the end of 2025, a 2.7% increase from 2024, and a 150.2% increase since 2015.

How much cash does Integra LifeSciences have?

In the past 10 years, Integra LifeSciences' cash and equivalents has ranged from $48.13 million in 2015 to $513.45 million in 2021, and is currently $235.05 million as of their latest financial filing in 2025.

How has Integra LifeSciences' book value per share changed over the last 10 years?

Over the last 10 years, Integra LifeSciences' book value per share changed from 20.32 in 2015 to 13.40 in 2025, a change of -34.1%.


Related Companies

Financial statements for NASDAQ:IART last updated on 3/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel